GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage
Brady Park(St. Michael's Hospital), Subodh Verma(St. Michael's Hospital), Ehab Bakbak(The University of Queensland), Aishwarya Krishnaraj(St. Michael's Hospital), David A. Hess(Western University), Javed Butler(Saint Luke's Health System), Adrian Quan(St. Michael's Hospital), Ori D. Rotstein(St. Michael's Hospital), Fallon Dennis(St. Michael's Hospital), Hwee Teoh(St. Michael's Hospital)
American Journal of Physiology-Heart and Circulatory Physiology
March 1, 2024
Cited by 98
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Mitochondrial function as a therapeutic target in heart failure
|Nature Reviews Cardiology|2016|786
New Markers of Inflammation and Endothelial Cell Activation
|Circulation|2003|733
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
|New England Journal of Medicine|2024|693